Wire · opportunities
Psychedelic therapy for TRD nears FDA approval, promising rapid, durable relief and broad adoption
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 September 2026 · Fusion42 review
A novel psychedelic therapy for treatment-resistant depression (TRD) is approaching FDA approval with phase III trials showing rapid and lasting efficacy. This treatment targets a large unmet patient need with strong payer interest and significant market potential, aiming for launch in early 2027.
This Wire brief sits within Fusion42's coverage of Mental Health.
◆ ◆ The Wire takeaway
You have a new treatment route opening thanks to the FDA nearing approval for psychedelic therapy in depression. Mental health startups can pivot or expand to meet this high-demand market sooner than expected.
◆ Coverage
1 source · 16 Sep 2026
◆ Related on Wire
◆ Topics